Home Science & Innovation Expanded access

Expanded access at Alfasigma

While clinical trials remain the primary pathway for accessing investigational medicines, we recognise that not all patients are eligible to participate.

In line with our commitment to ethical responsibility and patient care, we have established a policy to guide access to our investigational medicinal products outside of clinical trials. 

All requests for Expanded Access or Post-Trial Access must be submitted by a licensed treating physician. Alfasigma evaluates each request carefully, based on medical, ethical, and regulatory criteria, including: 

The severity of the patient’s condition and lack of alternatives 
The stage of development and availability of the investigational product 
The physician’s qualifications and agreement to comply with regulatory and safety standards

To initiate a request, physicians can submit an application through our secure online portal MyTomorrows: 

Please do not include any patient-identifying information in the request.

Click here to submit a request

For more information or questions

Physicians: [email protected]  
Patients and Caregivers: Please speak with your physician about whether this option may be appropriate for you.

Further information on expanded access and our approach is outlined in our policy.

Please note: Access is not guaranteed and may be discontinued at any time. This policy is subject to change.

Expanded access at Alfasigma

What is Expanded Access?

What is Post-Trial Access?

How to request access

For more information or questions